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Abstract
Blood vascular endothelial cells (BECs) and the de-
velopmentally related lymphatic endothelial cells
(LECs) create complementary, yet distinct vascular
networks. Each endothelial cell type interacts with
flowing fluid and circulating cells, yet each vascular
system has evolved specialized gene expression
programs and thus both cell types display different
phenotypes. BECs and LECs express distinct genes
that are unique to their specific vascular microenviron-
ment. Tumors also take advantage of the molecules
that are expressed in these vascular systems to
enhance their metastatic potential. We completed tran-
scriptome analyses on primary cultured LECs and
BECs, where each comparative set was isolated from
the same individual. Differences were resolved in the
expression of several major categories, such as cell
adhesion molecules (CAMs), cytokines, and cytokine
receptors. We have identified new molecules that
are associated with BECs (e.g., claudin-9, CXCL11,
neurexin-1, neurexin-2, and the neuronal growth factor
regulator-1) and LECs (e.g., claudin-7, CD58, hyalu-
ronan and proteoglycan link protein 1 (HAPLN1), and
the poliovirus receptor–related 3 molecule) that may
lead to novel therapeutic treatments for diseases of
lymphatic or blood vessels, including metastasis of
cancer to lymph nodes or distant organs.
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Introduction
The lymphatic system maintains tissue–fluid equilibrium
while organizing the surveillance for foreign antigens by
immune cells. Its smallest vessels are initial lymphatic
vessels that collect interstitial fluid and immune cells from
the surrounding tissue. These initial lymphatics consist of
lymphatic endothelial cells (LECs) that sit on a discontinu-
ous basement membrane and are tethered to the extracel-
lular matrix (ECM) through anchoring filaments. The
protein-rich lymph and extravasated immune cells enter
the initial lymphatic vessels through intercellular junctions,
are transported to a series of lymph nodes, and are then
returned to the blood primarily through the thoracic duct [1].
Initial lymphatics are different from blood vessel capillaries,
which are composed of blood vascular endothelial cells (BECs)
encircled by pericytes and basement membrane. It is of great
interest to distinguish the molecular differences between the
similar but different LECs and BECs.
The lymphatic system also plays a role in pathologic states
[2]. Lymphatic vessels act as a conduit for metastatic tumor
cells to escape from the primary tumor. Cells can be imaged in
lymphatic vessels in transit between the primary tumor and
sentinel lymph node in animals [3] and sentinel lymph node
biopsies positive for cancer cells serve as important determi-
nants of cancer prognosis and for the subsequent course of
therapy [4,5]. The molecular pathways involved with the devel-
opment and growth of the lymphatic system are beginning to be
understood. Molecules such as vascular endothelial growth
factor (VEGF)-C [6,7], VEGF-D [8], VEGF-A [9,10], hepatocyte
growth factor [11,12], and platelet-derived growth factor-BB
[13] have been shown to be lymphangiogenic. VEGF-A and
VEGF-C can also create hyperplastic tumor margin lymphatic
vessels when overexpressed [9,14]. The enlarged vessels
allow a greater number of metastatic cells to leave the primary
tumor, thus promoting metastasis [3,15].
In addition to aiding metastasis, the lymphatic system plays
a role in diseases involving lymphedema. Hereditary or primary
lymphedema occurs as a result of problems with the formation
of a functional lymphatic system. Some forms of primary
lymphedema have been linked to gene mutations in VEGFR-
3, i.e., the receptor for VEGF-C found on LECs [16]. Lymph-
edema can also occur as a result of an infection or injury to
the lymphatic systems, preventing lymphatic vessels from
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collecting lymph and returning to the blood. These secondary
forms of lymphedema are commonly caused by filarial infec-
tions or lymphatic vessel transection during surgery [17,18].
Research on lymphatic vessels and LECs has lagged
behind that of BECs and blood vessels. With the identifica-
tion of molecules that can distinguish LECs from BECs, the
field has grown tremendously. Yong et al. [19] used a spotted
oligonucleotide array to determine the gene expression
changes that occurred when LECs were subjected to
VEGF-C. In contrast to this study, previous comparisons of
the transcriptional expression of LECs and BECs [20–22]
did not have a full genome array available and did not make
the full data sets accessible. One recent study compared
cultured and uncultured LECs and BECs and found that
differences in the handling of the cells can change the
differential expression of the LECs and BECs [23].
Here we compare LECs and BECs with the largest pos-
sible gene array to identify differentially expressed genes that
will strengthen our understanding of lymphatic and blood vas-
cular biology and potentially uncover targets for therapeutic
intervention in lymphedema and lymphatic metastasis. We
used the Affymetrix GeneChip Human Genome U133 Plus
2.0 Array. Our analysis yields targets that may enhance our
understanding of lymphatic and blood vascular biology.
Materials and Methods
Cell Maintenance and Separation
Three independent lots of CD31+ human dermal micro-
vascular endothelial cells (HDMECs; PromoCell, Heidelberg,
Germany) isolated from different male individuals were
maintained on fibronectin-coated tissue culture plates in
endothelial cell growth medium MV low serum (PromoCell)
according to the manufacturer’s instructions. The isolation of
cells from separate individuals allowed us to compare LECs
and BECs from the same person, reducing the intrasample
variability. The cells were immunomagnetically separated
with mouse anti–human podoplanin IgG (a generous gift of
Dr. Dontscho Kerjaschki [24]). Cells were washed with PBS/
2% BSA solution and incubated in a magnetic particle con-
centrator (MPC-1; Invitrogen, Carlsbad, CA). Bead-bound
cells (LECs) were washed five times to remove all unbound
cells. Unbound cells in the wash buffer were collected and
centrifuged to pellets (900g for 3 minutes at room tempera-
ture). Unbound cells (BECs) were resuspended in wash
buffer and placed on the magnetic particle concentrator to
remove bead-bound cells; the process was repeated five
times. Pure populations of LECs (CD31+/podoplanin+) and
BECs (CD31+/podoplanin) were cultured in HDMEC media
and grown for two to four passages. Cells were used in
passage four to nine for microarray analysis and harvested at
approximately the same confluence.
RNA Isolation, Complementary RNA Preparation,
and Microarray Experiment
Total RNA was isolated from subconfluent LECs and
BECs with TRIzol reagent followed by a Qiagen RNA clean-
up procedure (RNeasy; Qiagen, Valencia, CA). Five micro-
grams of total RNA was used from each of the three
independent LEC and BEC preparations from cells isolated
from three separate individuals. Samples were submitted to
the Biopolymer Institute, a microarray core facility (Harvard
Medical School, Boston, MA). Total RNA (2.5–5 mg) was
used in the generation of the biotinylated complementary
RNA as recommended by the manufacturer using the One-
Cycle Eukaryotic Target Labeling Assay (Affymetrix, Santa
Clara, CA). Biotinylated targets were hybridized to an Affy-
metrix GeneChip Human Genome U133 Plus 2.0 Array with
the Gene Chip Hybridization Oven 640 (Affymetrix) and the
Gene Chip Fluidics Station 450 (Affymetrix). The hybridized
array was scanned with the Gene Chip Scanner 3000 7G
(Affymetrix). Affymetrix GeneChip Operating Software
(GCOS) performed a post run normalization by scaling the
data to the global mean of 500.
Quantitative Reverse Transcription–Polymerase Chain
Reaction (qRT-PCR)
Single-strand cDNA synthesis from total RNA was pre-
pared using TaqMan Reverse Transcription Reagents as re-
commended by the manufacturer (Applied Biosystems, Foster
City, CA). TaqMan Assays-On-Demand were purchased from
Applied Biosystems for HoxA5 (Hs00430330_m1), HoxA10
(Hs00538183_m1), Podoplanin (Hs00366764_m1), and Prox1
(Hs00160463_m1). The genesESX1 andBEX1were assayed
using Power SYBR Green-I (Applied Biosystems). Prim-
ers for the assay are as follows: ESX1, forward primer
5V–CTCAATATCCCGACGTTGTGG–3V and reverse primer
5V–CCAAACCTGCACTCTGTCTTCA–3V; BEX1, forward
primer 5V–GATAGGCCCAGGAGTAATGGAG–3V and re-
verse primer 5V–CTTGGTTGGCATTTTCCATG–3V; and
human glyceraldehyde-3-phosphate dehydrogenase, for-
ward primer 5V–CATGAGAAGTATGACAACAGCCT–3V
and reverse primer 5V–AGTCCTTCCACGATACCAAAGT–
3V. Each qRT-PCR performed was normalized to the endog-
enous glyceraldehyde-3-phosphate dehydrogenase levels
and calibrated to the relative BEC signal for each gene using
the DDCT method as previously described [25]. All qRT-PCR
analyses were performed in triplicate with ABI PRISM 7300
(Applied Biosystems).
Microarray Data Analysis
The unfiltered microarray data were subjected to X–Y
plot analysis using GCOS. Three independently obtained
LEC–BEC data pairs were superimposed on a single, log-
scale X–Y plot (X-axis: BEC mRNA expression; Y-axis: LEC
mRNA expression). Gene expression calls (Present/Absent)
were calculated using the default setting of GCOS and indi-
cated by color of each datum point: red, present in both BEC
and LEC; blue, absent in either BEC or LEC; yellow, absent
in both BEC and LEC. Datum points for representative BEC-
and LEC-specific genes were also indicated on the plot.
For gene ontology analysis, unfiltered microarray data
were uploaded into GeneSifter (www.genesifter.net), a web-
based analysis program with BEC data sets selected as
control. Normalized data was log2-transformed followed by
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applying a fold change filter of z 2.0 and a statistical t test
with a P < .05 cutoff (two-tailed unpaired Student’s t test
assuming equal variance). Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway analysis was performed
on the resultant probe sets and scored for significance. A
z-score of absolute value greater than 2 indicated whether a
pathway occurs more or less frequently than expected.
Extreme positive numbers (greater than 2) indicated that
the term occurred more frequently than expected, whereas
an extreme negative number (less than 2) indicated that
the term occurred less frequently than expected.
The data were additionally filtered by expression level,
selecting probe sets whose ratios were the result of having at
least one of the two comparisons (LECs or BECs) having a
log2-transformed expression level greater than 6.644 (this
number equals a scaled raw expression value of > 100) in the
numerator, i.e., LECs/BECs or BECs/LECs.
Two-dimensional hierarchical clustering analysis of 312 in-
formative genes was performed using Cluster software and vi-
sualized with TreeView software (Lawrence Berkeley National
Laboratories, Berkeley, CA) [26]. Complete linkage clustering
analysis was performed using an uncentered correlation as a
similarity metric for both genes and array data sets.
Results
Analysis of Microarray Data
We analyzed six individual Affymetrix gene arrays, three
from CD31+/podoplanin cell types and three from CD31+/
podoplanin+ cell types, hereafter referred to as BECs and
LECs, respectively. Each BEC and LEC cell line was isolated
from a mixed population of CD31+ HDMECs taken from the
same individual person, so each of the three sets was geneti-
cally identical. The mixed HDMEC population was immuno-
magnetically sorted into podoplanin-positive and -negative
cells with thorough washing. The cultures were compared
for podoplanin gene expression by measuring the amount of
podoplanin mRNA in each cell type by qRT-PCR. LECs had
podoplanin mRNA expression values ranging from 100- to
1500-fold higher than cultured BECs (data not shown).
To examine microarray data quality, scaled data were sub-
jected to scatterplot analysis of LECs versus BECs (Figure 1).
The overall shape of the plotted data showed a narrow,
symmetrical triangular contour pointing to the right upper
corner, which is typically observed when significantly similar
data sets are compared by this method. On the X–Y plot for
three superimposed BEC–LEC pair data sets, reproducible
detection of differential expression of several known LEC-
specific marker genes (i.e., podoplanin [PDPN], Prox-1, and
mannose receptor C, type I [MRC1]) and BEC-specific marker
genes (i.e., interferon, alpha-inducible protein 27 [IFI27],
STAT6, selectin E [SELE], and von Willebrand Factor [vWF])
are demonstrated. These results strongly support the notion
that the LEC and BEC cell preparations used in the present
study appropriately represented gene expression characteris-
tics for these cell types and that the microarray analysis of
differential gene expression was properly performed.
To further validate our gene array data, we choose repre-
sentative genes with altered gene expression in LECs and
BECs. Podoplanin and Prox-1 gene expression were mea-
sured because they are recognized as typical LEC-associated
molecules and were differentially expressed in LECs. These
genes were shown to have more abundant expression in
LECs than BECs using TaqMan and SYBR Green qRT-PCR
(Figure 2). Four other genes, ESX1, BEX1, HOXA5, and
HOXA10, were chosen for verification because they com-
prised a range of expression levels and they had not been
previously been associatedwith LECs.ESX1andBEX1exhib-
ited high levels of gene expression.ESX1wasmore abundant
than podoplanin using qRT-PCR (Figure 2). HOXA5 and
HOXA10 had similar relevant expression to Prox-1 (Figure 2).
This small subset of genes helps verify the original array data
and gives more confidence in the validity of the data.
To obtain objective evidence, we performed hierarchical
clustering analysis of genes differentially expressed between
LECs and BECs (Figure W1). The clustering algorithm
clearly separated the triplicate LEC and BEC data sets
(Figure W1A), providing preliminary lists of LEC/BEC cell
type–discriminating marker genes. Because the number of
genes that were expressed stronger in BECs (Figure W1B)
and in LECs (Figure W1C) were comparable, the clustering
analysis was unlikely to reflect nonspecific differences in cell
viability or lower RNA quality for one of these cell types.
Data from the scaled microarray results were subjected to
selection criteria and used to create a list of differentially ex-
pressedgenes. The initial selection criteria (1.5-fold differential
expression; t test P value < .05) identified 2287 probe sets;
1197 probe sets had a higher expression in LECs and 1090
probe sets had higher expression in BECs. This data set was
used for KEGGpathway analysis.We applied amore stringent
selection criteria by removing all probe sets with both LEC
and BEC log2-transformed intensity values less than 6.644
Figure 1. Gene expression characteristics of LEC and BEC cell types.
Microarray data were superimposed onto an X–Y plot and typical marker
genes were highlighted for each cell type. Prox1, prospero-related homeobox
1; MRC1, mannose receptor C, type I; PDPN, podoplanin; SELE, selectin E;
vWF, von Willebrand factor; STAT6, signal transducer and activator of
transcription 6; IFI27, interferon, alpha-inducible protein 27.
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(< 100 of a nontransformed scaled intensity value), which is
generally not detectable by qRT-PCR. There were 1262
probe sets that passed this additional selection (see Table W1);
699 for LECs and 563 for BECs. This data set was used to
generate the top 25 genes that demonstrated the highest
expression differences between LECs and BECs (Table 1).
Podoplanin had the highest fold change overall suggest-
ing it is an appropriate molecule to use to separate BECs and
LECs. The next highest expressed gene in LECs was the
hyaluronan and proteoglycan link protein 1 (HAPLN1), an
ECM-linking protein that acts as a stabilizer of the interaction
between versican and hyaluronan in various tissues [27].
Also included in the top 25 LEC genes were transcription
factors (BATF and ESX1), receptors (MRC1, SORL1,CNR1,
PRLHR, and CHRND), and several open reading frames of
unknown function or lacking description.
BECs also had a wide variety of genes expressed at higher
levels than in LECs. The interferon, alpha-inducible protein
27 (IFI27 ) was the highest differentially expressed gene for
BECs. The only cell-surface receptor in the BEC top 25 list
was EPH receptor A4 and was accompanied by the cell
adhesion molecule (CAM), selectin E, which was expressed
as expected [28]. Critical for extracellular signaling, the chemo-
kine ligands CXCL11 and CX3CL1 were represented.
We employed KEGG pathways analysis to group the
differentially expressed genes into known functional or bio-
chemical pathways. Table 2 lists the pathways identified
for LECs and BECs that were scored as significant (> j2j
z-score). Each pathway listed in Table 2 has the associated
genes listed in Tables W2 and W3. LECs had high z-scores
for the cell cycle, pyrimidine metabolism, and one carbon
pool by folate pathways, indicating optimal growth media
used in culturing the LECs compared to BECs. The calcium
signaling pathway also scored significantly for LECs.
Cell Adhesion Molecules
BECs scored high (> 4) for the carbazole degradation, 2,4-
dichlorobenzoate degradation, and CAM pathways (Table 2).
The carbazole degradation and 2,4-dichlorobenzoate degra-
dation pathways had few members within the array, possibly
because the pathway is new or still in development. Cell
adhesion molecules are of great importance to the structure
and function of blood and lymphatic vessels. Table 3 lists the
members of the CAM pathway identified by KEGG analysis.
Claudin-5 [25], intercellular adhesion molecule 1 [29],
inducible T-cell costimulator ligand (ICOSL) [30], CD58
[31], poliovirus receptor [32], protein tyrosine phosphatase,
receptor type, M [33,34], selectin E [28], and selectin P [35]
have been previously identified with vascular endothelial
cell–cell adhesion and were expected. Surprisingly, several
genes had not been reported as associated with BECs, such
as claudin-9, themajor histocompatibility complex class II DO
alpha and DR alpha, neurexin-2, neurexin-3, and neuronal
growth regulator-1. Nevertheless, all the CAM-associated
genes in Table 3 were novel for LEC expression.
Cytokines and Cytokine Receptors
Cytokines and their receptors are important features of
endothelial cells. BECs in this study express the following
genes that have not been previously reported for this endo-
thelial cell type. Chemokine (C–C motif) ligand 15 was
expressed nine-fold higher in BECs than in LECs. Chemo-
kine (C–C motif) ligand 19 was expressed five-fold higher in
BECs. Chemokine (C–X–C motif) ligand 11, expressed in
endothelial cells and hepatocytes [36,37], was expressed
in BECs at high levels (> 48-fold) compared to LECs in
this study.
NOTCH2, a member of the Notch transmembrane protein
family and usually expressed in BECs [38], was expressed
3.32-fold higher in LECs, as was HEY2 (9.9-fold), a tran-
scriptional product of downstream Notch signaling [39].
Discussion
Our data show that LECs have a transcriptional program
distinct from that of blood vascular endothelial cells. LECs
and BECs perform similar functions but in a different micro-
environment. Blood vascular endothelial cells line the lumen
of capillary tubular structures assisted by perivascular cells
and continuous basement membrane. Blood cells and fluid
pass through these tubes at high velocity and under consid-
erable pressure, which changes depending on the current
state of the physiology of the organism. Protein and fluid are
lost from the blood vascular system, bathing the surrounding
cells with extracellular fluid. Protein- and lipid-rich fluid enters
the initial lymphatic vessels along with immune cells en route
to the lymph nodes and eventually reenter the circulatory
system. LECs, the major component of the initial lymphatic
system, in contrast to BECs, have much slower fluid dynam-
ics. Lymph enters the lymphatic system through pressure-
induced fluid transport. The two endothelial cell types are
part of a vascular system, but with widely divergent physio-
logical needs and requirements.
The transcriptome snapshot of LECs and BECs helps us
to understand the differences and the similarities each cell
type has. Each is tethered to the ECM. Many more ECM
proteins are specifically required for proper BEC functioning.
Endothelial cells of blood vessels need to actively interact
with molecules displayed on other circulating cells, such as
Figure 2. qRT-PCR expression analysis. Error bars are the relative quan-
tification minimum and maximum.
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immune surveillance cells. It is not unusual to discover that
some genes expressed in BECs are associated with cell-
to-cell junction communication, such as claudin-9, which
appears to be a developmentally expressed claudin. Before
this report, only expression of claudin-9 in neonatal proximal
tubule endothelial cells forming tight junctions within the
mouse kidney was published [40]. The BECs isolated from
neonatal HDMECs taken from infant foreskin for this study
express claudin-9, but may not be expressed in adult BECs.
There is mounting evidence that the vascular and ner-
vous systems use common protein machinery to establish
the placement of vessels and nerves [41,42]. Neurexin-1,
neurexin-2, and the neuronal growth factor regulator-1 were
differentially expressed in BECs compared to LECs, pro-
viding another example of common usage in nerve and blood
vessels patterning.
LECs expressed several genes that have not been previ-
ously associatedwith the lymphatic system.CD58 costimulates
CD4(+) T-cells through the CD2–CD58 system by promoting
lipid raft formation [31]. The expression of CD58 by LECs may
indicate another location previously unknown that T-cell activa-
tion can occur, although this study does not indicate whether
the expression of CD58 occurs on the luminal side or on the
abluminal side of the initial lymphatic vessels.
The role of programmed cell death 1 ligand 2 (PDL2)
was examined when Zhang et al. [43] generated knockout
Table 1. List of 25 Highly Expressed Genes in LECs and BECs.
Probe Set ID Gene Description Ratio Gene Identifier Chromosome
LECs
204879_at PDPN Podoplanin* 428.1 NM_006474 1
205523_at HAPLN1 Hyaluronan and proteoglycan link protein 1* 148.4 U43328 5
204438_at MRC1 Mannose receptor, C type 1 71.0 NM_002438 10
212560_at SORL1 Sortilin-related receptor, L(DLR class) A repeats-containing 20.3 AV728268 11
218332_at BEX1 Brain-expressed, X-linked 1 18.3 NM_018476 X
1552445_a_at ESX1 Extraembryonic, spermatogenesis, homeobox 1 homolog (mouse) 17.9 NM_153448 X
205015_s_at TGFA Transforming growth factor, alpha 17.4 NM_003236 2
229029_at CAMK4 Calcium/calmodulin –dependent protein kinase IV 17.3 AI745230 5
213436_at CNR1 Cannabinoid receptor 1 (brain) 16.8 U73304 6
204301_at KBTBD11 Kelch repeat and BTB (POZ) domain containing 11 15.1 NM_014867 8
1559975_at BTG1 B-cell translocation gene 1, antiproliferative 14.8 BC009050 12
213974_at ADAMTSL3 ADAMTS-like 3 14.4 AB033059 15
205965_at BATF Basic leucine zipper transcription factor, ATF-like 13.3 NM_006399 14
218741_at CENPM Centromere protein M 13.1 NM_024053 22
223631_s_at C19orf33 Chromosome 19 open reading frame 33 12.7 AF213678 19
211959_at IGFBP5 Insulin-like growth factor binding protein 5 12.6 AW007532 2
220318_at EPN3 Epsin 3 12.6 NM_017957 17
1557196_a_at – cDNA DKFZp547B198 (from clone DKFZp547B198) 12.4 AL831886 X
229081_at SLC25A13 Solute carrier family 25, member 13 (citrin) 12.2 AW268880 7
208161_s_at ABCC3 ATP-binding cassette, subfamily C (CFTR/MRP), member 3 12.0 NM_020037 17
204393_s_at ACPP Acid phosphatase, prostate 11.5 NM_001099 3
231805_at PRLHR Prolactin releasing hormone receptor 11.5 AL563031 10
207024_at CHRND Cholinergic receptor, nicotinic, delta 11.5 NM_000751 2
238529_at – CDNA clone IMAGE:6342029 10.3 AA573088 1
236817_at DEADC1 Deaminase domain containing 1 10.3 AI336346 6
BECs
202411_at IFI27 Interferon, alpha-inducible protein 27 274.53 NM_005532 14
206211_at SELE Selectin E (endothelial adhesion molecule 1) 104.42 NM_000450 1
207173_x_at CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) 76.01 D21254 16
209994_s_at ABCB1 ATP-binding cassette, subfamily B (MDR/TAP), member 1 51.57 AF016535 7
210163_at CXCL11 Chemokine (C–X–C motif) ligand 11 48.73 AF030514 4
212554_at CAP2 CAP, adenylate cyclase–associated protein, 2 (yeast) 34.81 N90755 6
203881_s_at DMD Dystrophin (muscular dystrophy, Duchenne and Becker types) 33.64 NM_004010 X
244204_at PRR3 Proline-rich 3 19.89 W87300 6
209074_s_at FAM107A Family with sequence similarity 107, member A 18.51 AF089853 3
228617_at BIRC4BP XIAP-associated factor-1 17.7 AA142842 17
205174_s_at QPCT Glutaminyl-peptide cyclotransferase (glutaminyl cyclase) 16.07 NM_012413 2
201332_s_at STAT6 Signal transducer and activator of transcription 6, interleukin-4 induced 15.37 BC004973 12
1552902_a_at FOXP2 Forkhead box P2 15.32 NM_148898 7
209474_s_at ENTPD1 Ectonucleoside triphosphate diphosphohydrolase 15.16 AV717590 10
230109_at PDE7B Phosphodiesterase 7B 14.99 AI638433 6
226281_at DNER Delta/notch– like EGF repeat containing 14.38 BF059512 2
1566161_at MEIS2 Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse) 14.33 AA340499 15
230741_at – Full-length insert cDNA clone YX74D05 13.76 AI655467 12
210882_s_at TRO Trophinin 13.6 U04811 X
226992_at NOSTRIN Nitric oxide synthase trafficker 13.58 AK002203 2
228948_at EPHA4 EPH receptor A4 13.07 T15545 2
203687_at CX3CL1 Chemokine (C–X3–C motif) ligand 1 13.03 NM_002996 16
202718_at IGFBP2 Insulin-like growth factor –binding protein 2, 36 kDa 12.72 NM_000597 2
203153_at IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 12.66 NM_001548 10
239669_at HIST1H3D Histone cluster 1, H3d 12.54 AW006409 6
*This is the highest representative of multiple probe sets.
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mice. The heterozygous / animals were healthy; antigen-
presenting cells from Pdl2/ mice induced stronger T-cell
proliferation than was expected compared to wild-type cells
in vitro and in vivo. Zhang et al. also concluded that PDL2
negatively regulated T-cells and played an essential role in
immune tolerance.
Of interest, the poliovirus receptor–related 3 protein may
have cell-adhesive functions, but this has not been exten-
sively studied. However, poliovirus receptor–related 2 is
thought to participate in the regulation of hematopoietic/
endothelial homophilic cellular functions and act as an in-
tercellular junction protein [44]. Thus, poliovirus receptor–
related 3 protein may be a new CAM expressed on LECs that
helps LECs form cell–cell junctions conducive to lymph
formation and immune cell intravasation. In the same class
of proteins, LECs express claudin-7, which is associated
with tight junctions, which exclude water and solutes across
endothelial cells. Claudin-7 also excludes the lateral transfer of
lipids and membrane proteins in epithelial cells that defines
their apical and basolateral compartments. Claudin-7 may
perform the same function in LECs and maintain their polarity.
Cell signaling is an essential characteristic of BECs. Many
of the chemokine and chemokine receptors that were iden-
tified in this study have been associated with the blood
vascular system. These molecules may be significant as
many tumor cells express receptors for chemokines and
home to a metastatic niche. We have identified several
chemokines that have not previously been associated with
BECs. For example, chemokine (C–C) ligand 15 (CCL15)
[45] can act as a signal for endothelial cell mobilization and,
according to this study, BECs can also produce it, which may
be context-dependent.
Dendritic cells (DCs) express chemokine (C–C) ligand 19
(CCL19), which regulates DC trafficking and the recruiting of
naı¨ve T-cells to the area of DC activity [46]. Expression of
CCL19 in BECs indicates that the blood vascular endothe-
lium may take an active role in the recruiting of DCs to areas
of activity.
CXCL11 is known to be involved in the negative regulation
of angiogenesis [47] through the CXCR3 receptors during
interferon-g induction. Activated T-cells, usually of the Th1
subtype, internalize CXCR3 when bound to their cognate
ligand CXCL11 [48]. The expression of CXCL11 on LECs
indicates another possible mechanism to attract activated
T-cells to lymphatic vessels. Tumor cells may take advan-
tage of this attracting mechanism to actively home the lym-
phatic network.
Table 2. KEGG Pathway Summary for LECs and BECs.
Total z Score
List LEC BEC Array LEC BEC
(A) LEC KEGG Pathways
Cell cycle 26 22 4 112 7.98 0.26
Pyrimidine metabolism 13 10 3 90 3.14 0.35
One carbon pool by folate 4 3 1 16 2.80 0.45
Calcium signaling pathway 26 15 11 174 2.77 1.56
Circadian rhythm 3 3 0 18 2.54 0.87
Glycosphingolipid biosynthesis – neo-lactoseries 4 3 1 21 2.21 0.17
Insulin signaling pathway 2 1 1 134 2.10 1.97
Diterpenoid biosynthesis 1 1 0 4 2.01 0.41
Styrene degradation 2 1 1 4 2.01 2.13
(B) BEC KEGG Pathways
Carbazole degradation 1 0 1 1 0.21 4.87
2,4-Dichlorobenzoate degradation 2 0 2 5 0.48 4.08
Cell adhesion molecules 19 5 14 127 0.26 4.06
Fluorene degradation 1 0 1 2 0.30 3.30
Histidine metabolism 6 1 5 38 0.53 2.86
Glycosaminoglycan degradation 4 1 3 17 0.30 2.85
Parkinson’s disease 4 1 3 18 0.24 2.72
Glycan structures – degradation 5 1 4 29 0.25 2.67
1,1,1-Trichloro-2,2-bis(4-chlorophenyl)ethane degradation 1 0 1 3 0.37 2.58
Oxidative phosphorylation 1 1 0 121 1.95 2.29
Styrene degradation 2 1 1 4 2.01 2.13
Prion disease 3 1 2 13 0.58 2.08
Table 3. Cell Adhesion Molecules’ KEGG Pathway–Associated Genes.
BECs LECs
Claudin-5 CD58 molecule
Claudin-9 Claudin-7
Inducible T-cell costimulator ligand (ICOSL) Major histocompatibility
complex, class I, C
Intercellular adhesion molecule 1 (CD54) Major histocompatibility
complex, class II, DP
alpha 1
Major histocompatibility complex, class II,
DO alpha
Poliovirus receptor – related 3
Major histocompatibility complex, class II,
DR alpha
Neurexin-2
Neurexin-3
Neuronal growth regulator 1
Poliovirus receptor
Programmed cell death 1 ligand 2
Protein tyrosine phosphatase, receptor
type, M
Selectin E
Selectin P
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The expression of NOTCH2, a transcription factor, and its
downstream transcriptional product, HEY2 indicates active
Notch signaling in LECs. Notch signaling molecules are
known to determine the cell fate of many cell types and
developmental processes of several organs, including the
nervous system. Notch may act as one of the cell-fate
determinates for LECs.
In conclusion, this report confirms previous reports of
molecules that are important determinants for cellular func-
tion of LECs and BECs. We also report several molecules
that are newly associated with either LECs or BECs. Cell
signaling is very important for BECs, as they express many
more chemokine ligands and receptors, which may not be as
important for the LECs due to their different microenviron-
ment and need for cellular recruitment. The molecules
identified may also be tested as possible ligands that attract
tumor cells as they metastasize.
Extracellular adhesion molecules are more necessary for
the BECs to handle the stress and strain of rapid fluid flow
and ever changing blood vessel pressure. However, several
molecules were discovered that are expressed by LECs that
may lead to further characterization of LEC function, espe-
cially CD58 and the poliovirus receptor–related 3 molecules.
This study reveals additional molecular markers that may be
used as targets to modify either the lymphatic or the blood
vascular endothelium in pathologic states.
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